BRAF and Ehlers-Danlos syndrome, musculocontractural type: About 30–60% of PDTCs and ATCs show mutations in the BRAF gene; however, specific inhibitors that target oncogenic BRAF have shown a short-lasting therapeutical benefit as single agents.